New Report Now Available | Regenerative Medicine Research Series

Current Status and Future Outlook of Stem Cell and PRP Therapies in the Self-Pay Healthcare Market, 2026


～Growth Opportunities in Self-Pay Healthcare: Insights into Changing International Patient Demand, Cell Processing Systems, and Safety / Efficacy Assessment～

Publication Date	Price	Number of Pages
October 30, 2026	**JPY 385,000 (tax included)**	**35 pages**

Background and Objectives

- The market for regenerative medicine and cell therapy under Japan's Act on the Safety of Regenerative Medicine continued to grow in 2025, fueled by inbound medical tourism. Although growth is expected to slow due to a decline in patient numbers from China, the market is forecast to expand by 7% in 2026, supported by growing patient numbers from other Asian countries.
- Meanwhile, recent medical incidents have highlighted the growing importance of ensuring safety and efficacy. This report analyzes market trends and future prospects for self-pay regenerative medicine and cell therapy, as well as testing practices, needs, and challenges at medical institutions.

Market Size Trends for Stem Cell, PRP, and Fibroblast Therapies in the Self-Pay Healthcare Market



※Note: Market size figures include actual, estimated, and forecast values presented in this report.

Key Highlights of the Report

①Changes in International Patient Demand and Behavior

Examines international patient trends across key markets, including China, Vietnam, Thailand, and Taiwan, focusing on first-time and repeat patients and conversion rates from inquiries to treatments.

②Cell Processing Practices and Adoption of Related Products

Examines in-house and outsourced cell processing practices, including outsourcing partners, costs, post-culture shipping temperatures, and the equipment, reagents, and PRP kits used by medical institutions.

③Safety and Efficacy Testing / Challenges Faced by Medical Institutions

Examines cell safety and efficacy testing practices, the reasons for conducting or not conducting these tests, future treatment strategies, and interest in adopting new regenerative medicine and cell therapies.

Contents

P.

Tabulation and Analysis

1. Executive Summary ····· 1
2. Conditions treated with stem cell, PRP and fibroblast therapies ····· 2
3. Annual patient numbers ····· 3
4. International patient trends ····· 6
5. Treatment fees by type of regenerative medicine and cell therapy ····· 7
6. Proportion of patients interested in regenerative medicine and cell therapy who receive treatment ····· 10
7. Locations where therapeutic cells are processed ····· 11
8. Number of culture staff at institutions performing cell culture in-house ····· 13
9. Cell processing locations and products used for in-house cell processing ····· 14
10. Cell processing contractors, outsourcing costs and material selection ····· 22
11. Number of patients receiving cultured stem cell therapy by cell culture provider ····· 25
12. Post-culture shipping temperatures for institutions outsourcing stem cell culture ····· 26
13. Challenges and issues in regenerative medicine and cell therapy ····· 27
14. Cell safety testing practices ····· 28
15. Cell efficacy testing practices ····· 29
16. Potential applications to other diseases and treatments ····· 30
17. Future treatment strategies ····· 31
18. Market size trends for stem cell, PRP and fibroblast therapies ····· 32

Survey Questionnaire ····· 33

Note: Page numbers indicate the starting pages of each section in the report.

Study Overview

Study population

Medical institutions providing Class II and/or Class III regenerative medicine

Participating institutions (45)

Institutions providing both Class II and Class III regenerative medicine: 19 institutions
Institutions providing Class II regenerative medicine: 26 institutions

Survey Method

Online and In-Person Interviews

Fieldwork period

August–September 2026

Note: Dental PRP therapy and cancer immunotherapy are excluded from the analysis of Class III regenerative medicine.

Who Should Use This Report?

This report is intended for:

- ○Contract cell processing providers
- ○Manufacturers of cell culture equipment, reagents, and consumables
- ○Cell testing and evaluation service providers
- ○Medical institutions providing regenerative medicine and cell therapies

It provides valuable insights for identifying market opportunities, guiding product and service development, and developing business strategies.

Contact Information

Seed Planning, Inc.

113-0034, Japan
4F Yushima First Building, 3-19-11 Yushima, Bunkyo-ku, Tokyo
Email: info@seedplanning.co.jp
Website: https://www.seedplanning.co.jp/

Sample Pages from the Report

Selected examples of the charts, tables, and analysis included in the full report.

01 Executive Summary | Report p.1



02 Cell Processing Contractors | p.22



03 Cell Safety Testing | p.28



Sample pages are reproduced from the report.